Abiopharma

🔍 Borg Bjarne Erik Siwert (Director)

Company: RenX Enterprises Corp. (RENX)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 2,476,338 shares of Series C Convertible Preferred Stock at $2.895 per share (Derivative)
  Date: 2026-06-11 | Code: A | Exercise: 2026-06-11 | equity_swap_involved: 0 | shares_owned_after: 7,169.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3, F4, F1, F1, F5
• Acquired 619,084 shares of Warrant at $2.895 per share (Derivative)
  Date: 2026-06-11 | Code: A | Expires: 2031-06-11 | Exercise: 2026-06-11 | equity_swap_involved: 0 | shares_owned_after: 619,084.00 | transaction_form_type: 4 | Footnotes: F2, F2, F3, F5

Footnotes:

• F1: The shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") held by the Reporting Person are initially convertible into an aggregate of 2,476,338.51 shares of the Issuer's common stock at a price of $2.895 per share; provided, however, that the conversion price is subject to adjustment in certain circumstances, to a price not to fall below $1.50 per share, including in the event the Issuer sells or issues securities at a price that is less than $2.895 per share while the shares of Series C Preferred Stock are outstanding, which may result in the issuance of additional shares of common stock upon conversion of the shares of Series C Preferred Stock.
• F2: On June 11, 2026, the Issuer and Index Equity US LLC ("Index Equity"), an entity controlled by the Reporting Person, entered into an exchange agreement, pursuant to which $7,169,072.79 of principal and accrued interest outstanding owed under a promissory note held by Index Equity was exchanged for 7,169 shares of Series C Preferred Stock and a common stock purchase warrant to purchase up to 619,084 shares of the Issuer's common stock. The exchange agreement and the exchange of the promissory note for the shares of Series C Preferred Stock and the warrant were approved in advance by the Issuer's board of directors.
• F3: The shares of Series C Preferred Stock are convertible into shares of common stock and the Warrants are exercisable for shares of common stock at any time at the election of the holder; provided, however, that, to the extent required by the rules and regulations of the Nasdaq Stock Market, LLC, no shares of Series C Preferred Stock shall be convertible into shares of common stock and no Warrants shall be exercisable for shares of common stock unless and until stockholder approval of such conversions and exercises, respectively, is obtained.
• F4: The shares of Series C Preferred Stock do not expire.
• F5: The Reporting Person is the manager of Index Equity. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.